Physician profile
Scott C So
NPI 1942229984
$173,367.18
in general payments reported to CMS, 2019-2025
31 companies · $7,920 in 2025
The $7,920 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,571 · 2020: $22K · 2021: $18K · 2022: $51K · 2023: $44K · 2024: $25K · 2025: $7,920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Food and Beverage: $7,276 · Travel and Lodging: $3,647 · Consulting Fee: $3,300 · Long Term Medical Supply Or Device Loan: $501 · Education: $35.68 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,150.00 |
| Food and Beverage | $7,276.47 |
| Travel and Lodging | $3,646.90 |
| Consulting Fee | $3,300.00 |
| Long Term Medical Supply Or Device Loan | $501.40 |
| Education | $35.68 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $113,691.72 | 2022-2025 | Durysta, Lumigan, Vuity |
| Allergan, INC. | $40,552.01 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $6,093.30 | 2019-2021 | |
| Alcon Vision LLC | $1,951.90 | 2019-2025 | Rocklatan, Clareon, Simbrinza |
| Kala Pharmaceuticals, INC. | $1,869.16 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,693.79 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $1,556.25 | 2019-2023 | |
| Carl Zeiss Meditec USA, INC. | $1,442.38 | 2022-2024 | Lumera, Cirrus Hd-Oct |
| Bausch & Lomb Americas INC. | $721.06 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Sight Sciences, INC. | $665.07 | 2020-2024 | Omni Surgical System, Tearcare System |
| Glaukos Corporation | $415.17 | 2019-2023 | |
| Oyster Point Pharma, INC. | $390.80 | 2022-2024 | Tyrvaya |
| Thea Pharma INC. | $327.07 | 2022-2024 | Iyuzeh |
| Biotissue Holdings INC. | $299.94 | 2019-2023 | |
| Astellas Pharma US INC | $265.93 | 2023-2024 | Izervay |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $243.33 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $219.28 | 2019-2023 | Tecnis Iol, Tecnis Simplicity |
| Apellis Pharmaceuticals, INC. | $218.99 | 2022-2025 | Syfovre |
| Dutch Ophthalmic, USA | $165.50 | 2024 | Tissueblue, Eva, Combined Machine |
| Sun Pharmaceutical Industries INC. | $96.78 | 2019-2022 | |
| Ivantis, INC | $91.96 | 2020 | |
| Harrow Eye, LLC | $89.58 | 2025 | Vevye, Iheezo |
| Amgen INC. | $77.81 | 2024-2025 | Tepezza |
| Carl Zeiss Meditec, INC. | $50.46 | 2019 | |
| Shire North American Group INC | $41.48 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $39.76 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $27.63 | 2023 | Tepezza |
| Dompe US, INC. | $22.61 | 2024 | Oxervate |
| Genentech USA, INC. | $19.18 | 2024 | Vabysmo |
| Ocular Therapeutix, INC. | $17.39 | 2020 | |
| New World Medical,INC. | $9.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott So listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.